Gateway to Think Tanks
来源类型 | Working Paper |
规范类型 | 报告 |
DOI | 10.3386/w28071 |
来源ID | Working Paper 28071 |
Internal Deadlines, Drug Approvals, and Safety Problems | |
Lauren Cohen; Umit Gurun; Danielle Li | |
发表日期 | 2020-11-16 |
出版年 | 2020 |
语种 | 英语 |
摘要 | Absent explicit quotas, incentives, reporting, or fiscal year-end motives, drug approvals around the world surge in December, at month-ends, and before respective major national holidays. Drugs approved before these informal deadlines are associated with significantly more adverse effects, including more hospitalizations, life-threatening incidents, and deaths – particularly, drugs most rushed through the approval process. These patterns are consistent with a model in which regulators rush to meet internal production benchmarks associated with salient calendar periods: this “desk-clearing” behavior results in more lax review, leading both to increased output and increased safety issues at particular—and predictable—periodicities over the year. |
主题 | Health, Education, and Welfare ; Health ; Other ; Law and Economics ; Development and Growth ; Innovation and R& ; D ; Economic Systems |
URL | https://www.nber.org/papers/w28071 |
来源智库 | National Bureau of Economic Research (United States) |
引用统计 | |
资源类型 | 智库出版物 |
条目标识符 | http://119.78.100.153/handle/2XGU8XDN/585745 |
推荐引用方式 GB/T 7714 | Lauren Cohen,Umit Gurun,Danielle Li. Internal Deadlines, Drug Approvals, and Safety Problems. 2020. |
条目包含的文件 | ||||||
文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
w28071.pdf(3161KB) | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。